Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/181799
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcia Sangenís, Ana-
dc.contributor.authorMorros Pedrós, Rosa-
dc.contributor.authorAguilar Sánchez, Mercedes-
dc.contributor.authorMedina Perucha, Laura-
dc.contributor.authorLeiva, Alfonso-
dc.contributor.authorRipoll, Joana-
dc.contributor.authorMartínez Pecharromán, Mar-
dc.contributor.authorBartolomé Moreno, Cruz B-
dc.contributor.authorMagallon Botaya, Rosa-
dc.contributor.authorMarín Cañada, Jaime-
dc.contributor.authorMolero, José M.-
dc.contributor.authorMoragas, Ana-
dc.contributor.authorTroncoso, Amelia-
dc.contributor.authorMonfà, Ramon-
dc.contributor.authorLlor, Carl-
dc.date.accessioned2021-12-13T11:52:34Z-
dc.date.available2021-12-13T11:52:34Z-
dc.date.issued2021-11-01-
dc.identifier.issn2044-6055-
dc.identifier.urihttp://hdl.handle.net/2445/181799-
dc.description.abstractIntroduction: Uncomplicated lower urinary tract infections (uLUTI) are a common problem in primary care. Current local guidelines recommend the use of a single 3 g dose of fosfomycin. However, most general practitioners (GP) prefer short-course therapies to single-dose therapy. No study has compared head-to-head short-course antimicrobial agents for uLUTIs. Therefore, the aim of this randomised clinical trial is to compare three different short-course antibiotic therapies with a single-dose of fosfomycin for these infections. Methods and analysis: This will be a pragmatic, multicentre, parallel group, open trial. Women aged 18 or older and with symptoms of uLUTI and a positive urine dipstick analysis will be randomised to one of the following four groups: a single dose of 3 g of fosfomycin, 2 days of 3 g of fosfomycin o.d., 3 days of pivmecillinam 400 mg three times per day (t.i.d) or 5 days of nitrofurantoin 100 mg t.i.d. A total sample of 1120 patients was calculated. The primary endpoint is clinical effectiveness at day 7, defined as cure of symptoms reported by the patients in a diary including four symptoms: dysuria, urgency, frequency and suprapubic pain, which will be scored on a 4-point severity scale (not present/mild/moderate/severe). Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed. If positive, antibiograms for the three antibiotics studied will be performed. Bacterial eradication will be measured at days 14 and 28.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBMJ-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/bmjopen-2021-055898-
dc.relation.ispartofBMJ Open, 2021, vol. 11, num. 11-
dc.relation.urihttps://doi.org/10.1136/bmjopen-2021-055898-
dc.rightscc by-nc (c) Garcia Sangenís, Ana et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationInfeccions del tracte urinari-
dc.subject.classificationTerapèutica-
dc.subject.classificationAntibiòtics-
dc.subject.otherUrinary tract infections-
dc.subject.otherTherapeutics-
dc.subject.otherAntibiotics-
dc.titleClinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-12-10T08:11:31Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid34824124-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
e055898.full.pdf581.89 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons